Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Attenua, Inc.
This study will have two 21-day treatment periods separated by a 14-day washout period. There will be a 14-day follow-up period.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chest radiograph or computed tomography (CT) scan of the thorax within the last 1 year not demonstrating any abnormality considered to be significantly contributing to the refractory chronic cough
Diagnosis of refractory chronic cough or unexplained cough for at least one year
Women of child-bearing potential who use 2 forms of acceptable birth control method
Male subjects and their partners of child-bearing potential who use 2 methods of acceptable birth control
Has provided written informed consent
You may not be if
Current smoker (cigarettes or e-cigarettes) or has given up smoking within the past 12 months
Currently taking an ACE-inhibitor or requiring treatment with an ACE-inhibitor during the study or within 12 weeks prior to the Baseline Visit
Has an upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit
Has a history of cystic fibrosis
Has a history of malignancy within 5 years prior to the Baseline Visit
Has active hepatitis infection
Has a history of human immunodeficiency virus (HIV) infection
Has a positive test for any drug of abuse
Has a history of hypersensitivity to bradanicline or any of its components
Clareo Health | A Dose Escalation Study of Bradanicline in Refractory Chronic Cough
